Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Goodwill (2016 - 2017)

Celldex Therapeutics has reported Goodwill over the past 8 years, most recently at $91.0 million for Q4 2017.

  • Quarterly results put Goodwill at $91.0 million for Q4 2017, changed 0.0% from a year ago — trailing twelve months through Dec 2017 was $91.0 million (changed 0.0% YoY), and the annual figure for FY2017 was $91.0 million, changed 0.0%.
  • Goodwill for Q4 2017 was $91.0 million at Celldex Therapeutics, roughly flat from $91.0 million in the prior quarter.
  • Over the last five years, Goodwill for CLDX hit a ceiling of $91.0 million in Q4 2016 and a floor of $9.0 million in Q1 2013.
  • Median Goodwill over the past 5 years was $9.0 million (2013), compared with a mean of $29.5 million.
  • Biggest five-year swings in Goodwill: changed 0.0% in 2013 and later surged 914.79% in 2016.
  • Celldex Therapeutics' Goodwill stood at $9.0 million in 2013, then changed by 0.0% to $9.0 million in 2014, then changed by 0.0% to $9.0 million in 2015, then surged by 914.79% to $91.0 million in 2016, then changed by 0.0% to $91.0 million in 2017.
  • The last three reported values for Goodwill were $91.0 million (Q4 2017), $91.0 million (Q3 2017), and $91.0 million (Q2 2017) per Business Quant data.